Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | LATS1 | O95835 | 4/20 | 0.36 |
| ▸ | LATS2 | Q9NRM7 | 4/20 | 0.36 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | PRKCB | P05771 | 1/20 | 0.35 |
| ▸ | PRKCH | P24723 | 1/20 | 0.35 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30947591 | 0.84 | LOXL2 (0.41) | LOXL2LATS1LATS2KIF11PRKCB | |
| SCHEMBL30211245 | 0.83 | LOXL2 (0.39) | LOXL2LATS1LATS2PRKCBPRKCH | |
| SCHEMBL31407209 | 0.83 | LOXL2 (0.44) | LOXL2LATS1LATS2PRKCBPRKCH | |
| SCHEMBL1577535 | 0.83 | LOXL2 (0.39) | LOXL2LATS1LATS2PRKCBPRKCH | |
| SCHEMBL7808033 | 0.82 | LOXL2 (0.38) | LOXL2LATS1LATS2KIF11PRKCB | |
| SCHEMBL16472122 | 0.82 | LOXL2 (0.38) | LOXL2LATS1LATS2KIF11PRKCB | |
| SCHEMBL18626326 | 0.79 | LOXL2 (0.41) | LOXL2LATS1LATS2PRKCBPRKCH | |
| SCHEMBL2145747 | 0.79 | LOXL2 (0.43) | LOXL2KIF11 | |
| SCHEMBL1705592 | 0.78 | KIF11 (0.39) | LATS1KIF11ALOX5PTGS1PTGS2 | |
| SCHEMBL19440742 | 0.77 | LOXL2 (0.39) | LOXL2LATS1LATS2PRKCBPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-11912685-B2 | Biphenyl diaryl pyrimidine derivative with aromatic heterocyclic structure | FUDAN UNIVERSITY (CN) | 2024-02-27 | — | — | US | disclosed |
| US-11912685-B2 | Biphenyl diaryl pyrimidine derivative with aromatic heterocyclic structure | FUDAN UNIVERSITY (CN) | 2024-02-27 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100197657-A1 | 2-ARYL OR HETEROARYL INDOLE DERIVATIVES | CHANG RONALD K | 2010-08-05 | — | — | US | disclosed |
| US-20100197657-A1 | 2-ARYL OR HETEROARYL INDOLE DERIVATIVES | CHANG RONALD K | 2010-08-05 | — | — | US | disclosed |
| US-7737154-B2 | CRF receptor antagonists and methods relating thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2010-06-15 | — | — | US | disclosed |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-7456194-B2 | Imidazo-fused oxazolo [4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070275965-A1 | CXCR4 modulators | CHEMOCENTRYX, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | LOXL2 3088/4885LATS1 335/4885LATS2 286/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | LOXL2 4393/4885LATS1 2895/4885LATS2 2927/4885 |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK2A1 | LOXL2 4057/4885LATS1 1334/4885LATS2 1999/4885 |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | LOXL2 3032/4885LATS1 4797/4885LATS2 4827/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | LOXL2 3968/4885LATS1 4199/4885LATS2 4402/4885 |
| US-20100197657-A1 | 2-ARYL OR HETEROARYL INDOLE DERIVATIVES | ASIC1, ASIC3, TRPV1 | LOXL2 1306/4885LATS1 1446/4885LATS2 778/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | LOXL2 1690/4885LATS1 4128/4885LATS2 4023/4885 |
| US-11912685-B2 | Biphenyl diaryl pyrimidine derivative with aromatic heterocyclic structure | DPYD, TYMP, DHODH | LOXL2 4204/4885LATS1 3436/4885LATS2 3758/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | LOXL2 2918/4885LATS1 1165/4885LATS2 1468/4885 |
| US-20070275965-A1 | CXCR4 modulators | CXCL12, CXCR4, CXCR1 | LOXL2 4075/4885LATS1 1617/4885LATS2 1076/4885 |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | LOXL2 2916/4885LATS1 803/4885LATS2 1001/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | LOXL2 1304/4885LATS1 3541/4885LATS2 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.